Literature DB >> 19808440

Absence of pathognomonic or inflammatory patterns in cardiac biopsies from patients with Brugada syndrome.

Sven Zumhagen1, Tilmann Spieker, Julia Rolinck, Hideo A Baba, Günter Breithardt, Werner Böcker, Lars Eckardt, Matthias Paul, Thomas Wichter, Eric Schulze-Bahr.   

Abstract

BACKGROUND: Brugada syndrome (BrS) is characterized by the presence of coved ST-segment elevations in the right precordial leads (so-called type I ECG) and additional clinical features. Caused by cardiac ion channel gene mutations, BrS may be associated with ventricular and atrial conduction disturbances as well as ventricular fibrillation. Recent studies have discussed whether BrS is merely a primary electric disorder or whether inflammatory or other histopathologic abnormalities in the right ventricle (RV) underlie the ECG phenotype. METHODS AND
RESULTS: We retrospectively analyzed BrS biopsy samples from 21 unrelated patients for histopathologic abnormalities (hypertrophy, fibrosis, inflammation, fatty tissue) together with the patients' clinical, genetic, and imaging data. Eleven patients (52%) had normal RV imaging (by angiography, echocardiography, or cardiac MRI). Results of myocardial biopsies were normal in 3 patients (14%) and revealed mostly moderate abnormalities in the others. Four patients (19%) had predominant fatty tissue in the RV myocardium. Using immunohistochemistry and conventional tissue staining, we could not detect inflammatory tissue changes, an observation compatible with the clinical absence of signs for myocarditis.
CONCLUSIONS: Imaging and histopathologic evaluation may detect moderate but uncharacteristic cardiac abnormalities in patients with BrS. None of the patients had arrhythmogenic RV cardiomyopathy or overt myocarditis. Only in a small subset did predominant histopathologic abnormalities in the biopsy samples of the RV outflow tract occur that could provide a link to the ECG phenotype. A variety of mechanisms, including genetic and structural RV alterations, may underlie the Brugada ECG phenotype.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19808440     DOI: 10.1161/CIRCEP.107.737882

Source DB:  PubMed          Journal:  Circ Arrhythm Electrophysiol        ISSN: 1941-3084


  19 in total

Review 1.  Unmasking the molecular link between arrhythmogenic cardiomyopathy and Brugada syndrome.

Authors:  Javier Moncayo-Arlandi; Ramon Brugada
Journal:  Nat Rev Cardiol       Date:  2017-07-13       Impact factor: 32.419

Review 2.  Relationship Between Arrhythmogenic Right Ventricular Cardiomyopathy and Brugada Syndrome: New Insights From Molecular Biology and Clinical Implications.

Authors:  Domenico Corrado; Alessandro Zorzi; Marina Cerrone; Ilaria Rigato; Marco Mongillo; Barbara Bauce; Mario Delmar
Journal:  Circ Arrhythm Electrophysiol       Date:  2016-04

3.  The pathophysiological mechanism underlying Brugada syndrome: depolarization versus repolarization.

Authors:  Arthur A M Wilde; Pieter G Postema; José M Di Diego; Sami Viskin; Hiroshi Morita; Jeffrey M Fish; Charles Antzelevitch
Journal:  J Mol Cell Cardiol       Date:  2010-07-24       Impact factor: 5.000

4.  Isoproterenol-induced FKBP12.6/12 downregulation is modulated by ETA and ETB receptors and reversed by argirhein, a derivative of rhein.

Authors:  Guo-lin Zhang; De-zai Dai; Tao Xi; Xiao-dong Cong; Yun Zhang; Yin Dai
Journal:  Acta Pharmacol Sin       Date:  2011-02       Impact factor: 6.150

5.  Diagnostic dilemmas: overlapping features of brugada syndrome and arrhythmogenic right ventricular cardiomyopathy.

Authors:  Mark G Hoogendijk
Journal:  Front Physiol       Date:  2012-05-23       Impact factor: 4.566

6.  Brugada ECG pattern: a physiopathological prospective study based on clinical, electrophysiological, angiographic, and genetic findings.

Authors:  Guillaume Duthoit; Véronique Fressart; Françoise Hidden-Lucet; Françoise Simon; Darouna Kattygnarath; Philippe Charron; Caroline Himbert; Philip Aouate; Pascale Guicheney; Yves Lecarpentier; Robert Frank; Jean-Louis Hébert
Journal:  Front Physiol       Date:  2012-12-27       Impact factor: 4.566

7.  SCN5A mutations in Brugada syndrome are associated with increased cardiac dimensions and reduced contractility.

Authors:  Frans van Hoorn; Maria E Campian; Anje Spijkerboer; Marieke T Blom; R Nils Planken; Albert C van Rossum; Jacques M T de Bakker; Arthur A M Wilde; Maarten Groenink; Hanno L Tan
Journal:  PLoS One       Date:  2012-08-02       Impact factor: 3.240

8.  A review of the mechanisms of ventricular arrhythmia in brugada syndrome.

Authors:  J Bhar-Amato; Lm Nunn; Pd Lambiase
Journal:  Indian Pacing Electrophysiol J       Date:  2010-09-05

9.  C-reactive protein levels in the brugada syndrome.

Authors:  Aimé Bonny; Joelci Tonet; Manlio F Márquez; Antonio De Sisti; Abdou Temfemo; Caroline Himbert; Fatima Gueffaf; Fabrice Larrazet; Ivo Ditah; Robert Frank; Françoise Hidden-Lucet; Guy Fontaine
Journal:  Cardiol Res Pract       Date:  2011-11-29       Impact factor: 1.866

10.  A heterozygous deletion mutation in the cardiac sodium channel gene SCN5A with loss- and gain-of-function characteristics manifests as isolated conduction disease, without signs of Brugada or long QT syndrome.

Authors:  Sven Zumhagen; Marieke W Veldkamp; Birgit Stallmeyer; Antonius Baartscheer; Lars Eckardt; Matthias Paul; Carol Ann Remme; Zahurul A Bhuiyan; Connie R Bezzina; Eric Schulze-Bahr
Journal:  PLoS One       Date:  2013-06-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.